Security Snapshot

Mirum Pharmaceuticals, Inc. - Common Stock (MIRM) Institutional Ownership

CUSIP: 604749101

13F Institutional Holders and Ownership History from Q3 2019 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

324

Shares (Excl. Options)

71,449,611

Price

$117.07

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+4,549,743
Value change
+$601,784,306
Number of holders
324
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
60,919,423
SEC-reported price per share
$112.59
Insider filing price
$112.59
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • MIRM - Mirum Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 604749101.
  • 324 institutions reported positions in Q2 2026.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 308 to 324 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $6,293,543,826 to $8,364,755,364.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 324 institutions filings for Q2 2026.

Open SEC evidence

Security key

604749101

Latest holder period

Q2 2026

13F holders

324

13D/G owners

6

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
6
Security
MIRM
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Janus Henderson Group Ltd. 9.7% -18% $759,743,787 -$20,072,863 5,909,184 -2.6% JANUS HENDERSON GROUP Ltd. 30 Jun 2026
Frazier Life Sciences IX, L.P. 6.8% -8.6% $324,522,832 +$29,477,804 4,108,404 +10% Patrick J. Heron 23 Jan 2026
FMR LLC 6.2% $485,718,308 3,777,851 FMR LLC 30 Jun 2026
BlackRock, Inc. 5.7% $320,148,340 3,465,559 BlackRock, Inc. 31 Mar 2026
EVENTIDE ASSET MANAGEMENT, LLC 4.1% -27% $165,372,042 -$40,549,990 2,093,582 -20% Eventide Asset Management, LLC 31 Dec 2025
BIOTECHNOLOGY VALUE FUND L P 3% $109,619,710 1,495,290 BVF PARTNERS L P/IL 30 Sep 2025

As of 30 Jun 2026, 324 institutional investors reported holding 71,449,611 shares of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM). This represents 117% of the company’s total 60,919,423 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
81%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Frazier Life Sciences Management, L.P. 13% 7,679,684 0% 20% $899,060,606
Jupiter Topco LLC 9.7% 5,909,184 0% 0.28% $691,671,568
BlackRock, Inc. 7.2% 4,390,063 +14% 0.01% $513,944,677
FMR LLC 6% 3,670,314 +87% 0.02% $429,683,688
PRICE T ROWE ASSOCIATES INC /MD/ 4.4% 2,655,607 +55% 0.03% $310,893,000
VANGUARD PORTFOLIO MANAGEMENT LLC 3.9% 2,377,019 +66% 0.01% $278,277,614
VANGUARD CAPITAL MANAGEMENT LLC 3.7% 2,254,109 -6.7% 0.01% $263,888,541
STATE STREET CORP 3.6% 2,170,689 +12% 0.01% $254,122,561
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 2.3% 1,404,741 +318% 0.49% $164,453,029
GEODE CAPITAL MANAGEMENT, LLC 2.3% 1,393,908 +11% 0.01% $163,213,962
Invesco Ltd. 2.2% 1,364,084 +378% 0.01% $159,693,314
WELLINGTON MANAGEMENT GROUP LLP 2.2% 1,309,987 -1.9% 0.03% $153,360,177
EVENTIDE ASSET MANAGEMENT, LLC 2% 1,248,389 -11% 2% $146,202,247
TANG CAPITAL MANAGEMENT LLC 2% 1,236,027 0% 6.6% $144,701,681
Capital World Investors 1.9% 1,153,480 +59% 0.02% $135,037,904
FRANKLIN RESOURCES INC 1.9% 1,152,770 +61% 0.03% $134,954,787
NOVO HOLDINGS A/S 1.8% 1,125,000 -15% 7.7% $131,703,750
TCG Crossover Management, LLC 1.7% 1,062,049 0% 3% $124,334,076
BVF INC/IL 1.7% 1,056,027 -33% 3.2% $123,629,081
Polar Capital Holdings Plc 1.4% 845,524 +198% 0.28% $98,985,495
Rock Springs Capital Management LP 1.3% 798,145 -1.6% 4.6% $93,438,835
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 1.2% 752,044 +86% 0.13% $88,042,000
AMERIPRISE FINANCIAL INC 1.2% 726,694 +231% 0.02% $85,074,348
TWO SIGMA INVESTMENTS, LP 1.1% 690,318 -11% 0.06% $80,815,528
Bank of New York Mellon Corp 1.1% 669,974 +15% 0.01% $78,433,863

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
28
Latest
Q2 2026
Rows shown
1-25 of 28
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 71,449,611 $8,364,755,364 +$601,784,306 $117.07 324
2026 Q1 68,242,328 $6,293,543,826 +$497,938,606 $92.38 308
2025 Q4 61,030,006 $4,820,619,551 +$288,257,634 $78.99 280
2025 Q3 57,251,922 $4,197,137,135 +$132,883,151 $73.31 268
2025 Q2 55,393,029 $2,819,019,204 +$70,434,976 $50.89 211
2025 Q1 54,142,705 $2,443,759,313 +$49,081,267 $45.05 213
2024 Q4 52,986,109 $2,190,964,431 -$26,045,809 $41.35 204
2024 Q3 53,301,609 $2,079,251,226 -$2,890,149 $39.00 176
2024 Q2 53,362,791 $1,824,471,702 +$17,964,526 $34.19 157
2024 Q1 53,243,448 $1,337,601,222 +$70,337,692 $25.12 167
2023 Q4 50,259,606 $1,483,847,413 +$1,676,068 $29.52 184
2023 Q3 48,930,333 $1,545,592,030 +$398,674,334 $31.60 156
2023 Q2 36,937,639 $955,518,729 +$63,103,719 $25.87 143
2023 Q1 34,669,406 $832,753,531 +$33,992,984 $24.02 114
2022 Q4 33,331,988 $650,146,380 -$12,725,497 $19.50 101
2022 Q3 33,748,714 $709,089,633 +$93,197,315 $21.01 107
2022 Q2 29,289,263 $568,434,366 +$47,575,699 $19.46 104
2022 Q1 26,813,353 $590,437,915 -$6,195,298 $22.02 99
2021 Q4 22,891,220 $365,087,000 +$18,990,411 $15.95 81
2021 Q3 21,414,209 $426,514,254 +$2,080,056 $19.92 69
2021 Q2 21,482,092 $371,413,185 +$642,669 $17.29 66
2021 Q1 21,451,984 $425,174,000 -$8,433,468 $19.82 60
2020 Q4 22,010,623 $384,380,000 +$52,268,047 $17.46 71
2020 Q3 18,743,135 $361,180,000 -$1,290,295 $19.27 50
2020 Q2 18,808,446 $366,015,000 +$8,936,163 $19.46 57
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .